Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.338
C. Marella, C. Malpangotto, D. Pezzella, M. Giolito, A. Martino, C. Rasca, M. Massa
{"title":"5PSQ-219 The role of the hospital pharmacist in monitoring drugs and medications prescription in the home care service: a guarantee of appropriateness","authors":"C. Marella, C. Malpangotto, D. Pezzella, M. Giolito, A. Martino, C. Rasca, M. Massa","doi":"10.1136/EJHPHARM-2021-EAHPCONF.338","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.338","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79103833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.273
A. Fernández, L. Lope, L. V. Torres, J. M. Rodríguez, C. Castillo-Martin, M. Izquierdo
{"title":"5PSQ-154 Determination of genetic polymorphisms of the dihydropyrimidine dehydrogenase gene in real clinical practice as predictors of severe fluoropyrimidine associated toxicity","authors":"A. Fernández, L. Lope, L. V. Torres, J. M. Rodríguez, C. Castillo-Martin, M. Izquierdo","doi":"10.1136/EJHPHARM-2021-EAHPCONF.273","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.273","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73729794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.224
A. Fernandes, A. Brito, T. Mendes, A. Alcobia
Background and importanceIn the context of the COVID-19 pandemic, many patients avoided moving from their homes, even to acquire essential drugs, such as antiretroviral therapy (ART) High adherence (more than 95%) is essential to acquire viral suppression and is associated with reduced mortality and morbidity Furthermore, poor ART adherence is the first cause of therapeutic failure in HIV patients and HIV drug resistant strains Aim and objectivesTo evaluate and characterise the effect of the COVID-19 pandemic on adherence to ART and identify the main factors that influenced adherence during the pandemic Material and methodsA retrospective, transversal, comparative study was conducted over the first semester of 2019 and 2020 HIV patients receiving ART were included Exclusion criteria were: deaths, initiated ART during or after the first semester in 2019 and transfer to another hospital To measure adherence, dispensing records were analysed Registered variables were sex, risk factors that could compromise adherence and pill numbers Data were obtained from the electronic medical records For the statistical analysis, the paired t test was used to determine if there were differences in patient adherence before and after the COVID-19 pandemic Results100 patients were analysed during the study period, with an average age of 48 9±12 3 years and 61% were men ART adherence was 67% in 2019 (67% male non-adherent) whereas in 2020 it was 43% (58% male non-adherent) Comparing both years, there was a decrease of 24% in the adherence rate, which was significant (p=0 006) The main reasons for this reduction were: rescheduling of doctor appointments or blood tests, mandatory confinement due to COVID-19 or fear of using the hospital facilities Conclusion and relevanceThe study results suggested that the COVID-19 pandemic affected HIV patient adherence All efforts made to ensure continuity of treatment (medication delivery in the community and hospital pharmacies, teleconsultation) were not enough It is important that pharmacists continue to promote therapeutic adherence and education about COVID-19 The main limitation of the study was the reduced sample used It is highly important to monitor patients with ART to ensure their adherence rate and to understand how and why the COVID-19 pandemic affected their treatment Further research is needed to know the real impact of the COVID-19 pandemic on the health of HIV patients References and/or acknowledgementsConflict of interestNo conflict of interest
{"title":"4CPS-392 Effect of COVID-19 pandemic on antiretroviral therapy adherence","authors":"A. Fernandes, A. Brito, T. Mendes, A. Alcobia","doi":"10.1136/EJHPHARM-2021-EAHPCONF.224","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.224","url":null,"abstract":"Background and importanceIn the context of the COVID-19 pandemic, many patients avoided moving from their homes, even to acquire essential drugs, such as antiretroviral therapy (ART) High adherence (more than 95%) is essential to acquire viral suppression and is associated with reduced mortality and morbidity Furthermore, poor ART adherence is the first cause of therapeutic failure in HIV patients and HIV drug resistant strains Aim and objectivesTo evaluate and characterise the effect of the COVID-19 pandemic on adherence to ART and identify the main factors that influenced adherence during the pandemic Material and methodsA retrospective, transversal, comparative study was conducted over the first semester of 2019 and 2020 HIV patients receiving ART were included Exclusion criteria were: deaths, initiated ART during or after the first semester in 2019 and transfer to another hospital To measure adherence, dispensing records were analysed Registered variables were sex, risk factors that could compromise adherence and pill numbers Data were obtained from the electronic medical records For the statistical analysis, the paired t test was used to determine if there were differences in patient adherence before and after the COVID-19 pandemic Results100 patients were analysed during the study period, with an average age of 48 9±12 3 years and 61% were men ART adherence was 67% in 2019 (67% male non-adherent) whereas in 2020 it was 43% (58% male non-adherent) Comparing both years, there was a decrease of 24% in the adherence rate, which was significant (p=0 006) The main reasons for this reduction were: rescheduling of doctor appointments or blood tests, mandatory confinement due to COVID-19 or fear of using the hospital facilities Conclusion and relevanceThe study results suggested that the COVID-19 pandemic affected HIV patient adherence All efforts made to ensure continuity of treatment (medication delivery in the community and hospital pharmacies, teleconsultation) were not enough It is important that pharmacists continue to promote therapeutic adherence and education about COVID-19 The main limitation of the study was the reduced sample used It is highly important to monitor patients with ART to ensure their adherence rate and to understand how and why the COVID-19 pandemic affected their treatment Further research is needed to know the real impact of the COVID-19 pandemic on the health of HIV patients References and/or acknowledgementsConflict of interestNo conflict of interest","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84826348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.342
J. Rodrigo, A. F. García, L. Valdivieso, S. Ugarte, G. M. Pérez, D. B. Hernández
{"title":"5PSQ-223 Drugs to avoid. An opportunity in healthcare patients: checking Prescrire’s recommendations","authors":"J. Rodrigo, A. F. García, L. Valdivieso, S. Ugarte, G. M. Pérez, D. B. Hernández","doi":"10.1136/EJHPHARM-2021-EAHPCONF.342","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.342","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86706421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.339
E. Prado-Mel, H. Rodríguez-Ramallo, C. Gonzalez-Florencio
{"title":"5PSQ-220 Discrepancies between prescription and dispensing of medication in automatic dispensing cabinet","authors":"E. Prado-Mel, H. Rodríguez-Ramallo, C. Gonzalez-Florencio","doi":"10.1136/EJHPHARM-2021-EAHPCONF.339","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.339","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85092424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.90
J. Urda-Romacho, J. Canto-Mangana, M. Vida, C. Pinto-Nieto
{"title":"4CPS-258 Evaluation of medicines adherence and associated factors in patients with chronic hepatitis B","authors":"J. Urda-Romacho, J. Canto-Mangana, M. Vida, C. Pinto-Nieto","doi":"10.1136/EJHPHARM-2021-EAHPCONF.90","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.90","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89569164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.293
N. M. Pete, M. Montoro, C. P. Ramírez, A. E. Rodriguez, A. J. Morales
{"title":"5PSQ-174 Effectiveness and safety of abatacept therapy in patients with rheumatoid arthritis after previous failure with TNFi treatment","authors":"N. M. Pete, M. Montoro, C. P. Ramírez, A. E. Rodriguez, A. J. Morales","doi":"10.1136/EJHPHARM-2021-EAHPCONF.293","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.293","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77959413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.208
D. Rubio Calvo, M. Gutiérrez Lorenzo, J. Urda Romacho, C. Pinto Nieto, M. C. Castro Vida
{"title":"4CPS-376 Antiretroviral therapy optimisation strategies in patients infected with human immunodeficiency virus: a decisive task for hospital pharmacists","authors":"D. Rubio Calvo, M. Gutiérrez Lorenzo, J. Urda Romacho, C. Pinto Nieto, M. C. Castro Vida","doi":"10.1136/EJHPHARM-2021-EAHPCONF.208","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.208","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82598358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.19
MI Barcia Martin, C. Aguilar Guisado, S. Sanchez Suarez, M. Garcia Gimeno
Background and importanceBecause of the current pandemic, it was necessary to create an intensive care unit (ICU) in our hospital This meant an increase in the consumption of propofol and the associated supply problems It was necessary to develop a procedure to rationalise its use and administration Aim and objectivesTo describe the centralisation in the hospital pharmacy service of the reconditioning of propofol in bags to optimise its administration in the ICU during the COVID-19 pandemic Material and methodsThe ICU contacted the pharmacy service to express the need for higher volume presentations of propofol In response, a literature review was conducted to ascertain the possibility of reconditioning propofol in higher volume containers The stability of propofol in different primary packaging materials was reviewed to select the most appropriate The risk matrix for sterile preparations from the ‘Guide to good practice in the preparation of medicines in hospital pharmacy services’ was applied to draw up the standard working procedure and to establish the processing conditions, stability of the preparation and storage conditions A centralised propofol reconditioning procedure (CPRP) was established in the pharmacy service: under sterile conditions, transfer the propofol into an ethylene-vinyl-acetate bag to obtain a final volume of 500 mL (10 mg/mL) (using a 0 22 µm filter if the initial packaging is glass) It was sealed, labelled and packed in a photo protective bag The established stability was 7 days refrigerated or 30 hours at room temperature A descriptive retrospective study was carried out from its implementation (20 March 2020) to the date of closure of the ICU (5 May 2020) to determine the volume of reconditioned propofol and number of patients treated Data were collected from the electronic medical record and pharmacy programmes ResultsDuring this period, 258 propofol bags were produced Reconditioned propofol was dispensed to 16 patients (median age 59 years (range 41–83);62 5% men) The median number of bags per patient was 13 5 (range 3–66) Conclusion and relevanceThe CPRP in the pharmacy service increases the safety of administration, allows preparation under aseptic conditions and enables the optimisation of available stock As it contains more volume, it facilitates the work and protects the nursing staff by reducing the frequency of contact with the patient References and/or acknowledgementsConflict of interestNo conflict of interest
背景和重要性由于当前的大流行，有必要创建一个重症监护病房(ICU)医院这意味着增加消费的异丙酚和相关的供应问题有必要开发一个程序合理化使用和管理目标和objectivesTo描述医院药学服务的集中化的异丙酚整理袋来优化其政府在ICU COVID-19流行材料和methodsThe ICU联系了药房服务表示需要更大剂量的异丙酚对异丙酚在不同主要包装材料中的稳定性进行了评价，以选择最合适的包装材料。应用《医院药房药品配制良好规范指南》中的无菌制剂风险矩阵，制定了标准工作程序，并确定了加工条件。在药房服务中建立了集中异丙酚修复程序(CPRP):在无菌条件下，将异丙酚转移到乙烯-乙烯-醋酸酯袋中，最终体积为500 mL (10 mg/mL)(如果初始包装为玻璃，则使用0.22µm过滤器)。确定的稳定性为冷藏7天或室温30小时。从实施(2020年3月20日)到ICU关闭之日(2020年5月5日)进行了描述性回顾性研究，以确定修复异丙酚的量和治疗的患者人数。数据收集自电子病历和药房规划。共生产258袋异丙酚，16例患者(年龄中位数为59岁(41-83岁)，62.5%为男性)使用修复异丙酚，每位患者平均使用135袋(范围3-66)结论及相关性药学服务中的CPRP提高了给药安全性，允许在无菌条件下制备，并使可用库存优化，因为它含有更多的体积。它通过减少与病人接触的频率来促进工作并保护护理人员参考文献和/或致谢利益冲突无利益冲突
{"title":"2SPD-036 Centralised propofol reconditioning procedure during COVID-19","authors":"MI Barcia Martin, C. Aguilar Guisado, S. Sanchez Suarez, M. Garcia Gimeno","doi":"10.1136/EJHPHARM-2021-EAHPCONF.19","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.19","url":null,"abstract":"Background and importanceBecause of the current pandemic, it was necessary to create an intensive care unit (ICU) in our hospital This meant an increase in the consumption of propofol and the associated supply problems It was necessary to develop a procedure to rationalise its use and administration Aim and objectivesTo describe the centralisation in the hospital pharmacy service of the reconditioning of propofol in bags to optimise its administration in the ICU during the COVID-19 pandemic Material and methodsThe ICU contacted the pharmacy service to express the need for higher volume presentations of propofol In response, a literature review was conducted to ascertain the possibility of reconditioning propofol in higher volume containers The stability of propofol in different primary packaging materials was reviewed to select the most appropriate The risk matrix for sterile preparations from the ‘Guide to good practice in the preparation of medicines in hospital pharmacy services’ was applied to draw up the standard working procedure and to establish the processing conditions, stability of the preparation and storage conditions A centralised propofol reconditioning procedure (CPRP) was established in the pharmacy service: under sterile conditions, transfer the propofol into an ethylene-vinyl-acetate bag to obtain a final volume of 500 mL (10 mg/mL) (using a 0 22 µm filter if the initial packaging is glass) It was sealed, labelled and packed in a photo protective bag The established stability was 7 days refrigerated or 30 hours at room temperature A descriptive retrospective study was carried out from its implementation (20 March 2020) to the date of closure of the ICU (5 May 2020) to determine the volume of reconditioned propofol and number of patients treated Data were collected from the electronic medical record and pharmacy programmes ResultsDuring this period, 258 propofol bags were produced Reconditioned propofol was dispensed to 16 patients (median age 59 years (range 41–83);62 5% men) The median number of bags per patient was 13 5 (range 3–66) Conclusion and relevanceThe CPRP in the pharmacy service increases the safety of administration, allows preparation under aseptic conditions and enables the optimisation of available stock As it contains more volume, it facilitates the work and protects the nursing staff by reducing the frequency of contact with the patient References and/or acknowledgementsConflict of interestNo conflict of interest","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85669783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.147
R. Fernandez-Caballero, V. Arroyo, C. Herranz-Muñoz, A. Henares-López
Background and importance From the beginning of the COVID-19 pandemic, tocilizumab has been positioned as an effective drug to treat cytokine release syndrome, which causes acute respiratory distress in patients with SARS-CoV2 pneumonia. Throughout these months, clinical protocols have been developed that improve the effectiveness, introducing it at the onset of symptoms. Aim and objectives To evaluate if the change in criteria for treatment with tocilizumab between the first and second waves of the COVID-19 pandemic, introducing it at the onset of symptoms, led to an improvement in its effectiveness. Material and methods A retrospective observational study was conducted between 3 March 2020 and 15 October 2020 in patients with COVID-19 confirmed by PCR, treated with tocilizumab in a first level hospital. Demographic, clinical and pharmacotherapeutic data were collected from electronic medical records. To compare the effectiveness of treatment between the first COVID-19 wave (3 March to 31 May 2020) and the second COVID-19 wave (31 May to 15 October), we collected for each patient: days from admission to tocilizumab administration, oxygen therapy requirement, ICU stay, hospital stay and survival. Differences between quantitative and qualitative variables were analysed, applying the Student’s t test and the χ2 test (p≤0.005). Statistical analysis was performed with SPSS22.0. Results 167 patients (131 men), average age 58.9±12.6 years, were included. During the first wave, tocilizumab was administered to 100 patients. Days (average) until administration was 5±4.4. Length of hospital stay was 22.9±15.9 days. 39.0% of patients needed a stay in the ICU. Distribution of patients according to requirement for oxygen therapy: 48% high flow (HF) oxygen delivery systems, 19% low flow (LF) oxygen delivery systems and 31% with invasive mechanical ventilation. Two patients did not require oxygen therapy. The mortality rate was 28%. During the second wave, tocilizumab was administered to 67. Days (average) until administration was 2±2.2. Length (average) of hospital admission was 13.1±10.4 days. 10.1% of patients needed a stay in the ICU. Distribution of patients according to requirement for oxygen therapy: 11.6% HF and 88.4% LF. The mortality rate was 11.6%. We found statistically significant differences in length of hospital stay and mortality rate between the two groups. Conclusion and relevance The study showed that early administration of tocilizumab increased survival, decreased ICU income and shortened hospital stay. A limitation of our study was the lack of comparison between inflammatory parameters before and after administration. Further studies are needed. References and/or acknowledgements Conflict of interest No conflict of interest
{"title":"4CPS-315 Evaluation of the effectiveness of early administration of tocilizumab in patients with COVID-19","authors":"R. Fernandez-Caballero, V. Arroyo, C. Herranz-Muñoz, A. Henares-López","doi":"10.1136/EJHPHARM-2021-EAHPCONF.147","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.147","url":null,"abstract":"Background and importance From the beginning of the COVID-19 pandemic, tocilizumab has been positioned as an effective drug to treat cytokine release syndrome, which causes acute respiratory distress in patients with SARS-CoV2 pneumonia. Throughout these months, clinical protocols have been developed that improve the effectiveness, introducing it at the onset of symptoms. Aim and objectives To evaluate if the change in criteria for treatment with tocilizumab between the first and second waves of the COVID-19 pandemic, introducing it at the onset of symptoms, led to an improvement in its effectiveness. Material and methods A retrospective observational study was conducted between 3 March 2020 and 15 October 2020 in patients with COVID-19 confirmed by PCR, treated with tocilizumab in a first level hospital. Demographic, clinical and pharmacotherapeutic data were collected from electronic medical records. To compare the effectiveness of treatment between the first COVID-19 wave (3 March to 31 May 2020) and the second COVID-19 wave (31 May to 15 October), we collected for each patient: days from admission to tocilizumab administration, oxygen therapy requirement, ICU stay, hospital stay and survival. Differences between quantitative and qualitative variables were analysed, applying the Student’s t test and the χ2 test (p≤0.005). Statistical analysis was performed with SPSS22.0. Results 167 patients (131 men), average age 58.9±12.6 years, were included. During the first wave, tocilizumab was administered to 100 patients. Days (average) until administration was 5±4.4. Length of hospital stay was 22.9±15.9 days. 39.0% of patients needed a stay in the ICU. Distribution of patients according to requirement for oxygen therapy: 48% high flow (HF) oxygen delivery systems, 19% low flow (LF) oxygen delivery systems and 31% with invasive mechanical ventilation. Two patients did not require oxygen therapy. The mortality rate was 28%. During the second wave, tocilizumab was administered to 67. Days (average) until administration was 2±2.2. Length (average) of hospital admission was 13.1±10.4 days. 10.1% of patients needed a stay in the ICU. Distribution of patients according to requirement for oxygen therapy: 11.6% HF and 88.4% LF. The mortality rate was 11.6%. We found statistically significant differences in length of hospital stay and mortality rate between the two groups. Conclusion and relevance The study showed that early administration of tocilizumab increased survival, decreased ICU income and shortened hospital stay. A limitation of our study was the lack of comparison between inflammatory parameters before and after administration. Further studies are needed. References and/or acknowledgements Conflict of interest No conflict of interest","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80074493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：